A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses
详细信息 查看全文
- 作者：Pooja Khandelwal1 ; 2 ; pooja.khandelwal@cchmc.org" class="auth_mail" title="E-mail the corresponding author ; Tsuyoshi Fukuda2 ; 3 ; Kana Mizuno2 ; 3 ; Ashley Teusink-Cross4 ; Parinda A. Mehta1 ; 2 ; Rebecca A. Marsh1 ; 2 ; Angela D.M. Kashuba5 ; Alexander A. Vinks2 ; 3 ; Stella M. Davies1 ; 2
- 关键词：Maraviroc ; Chemokine receptor type 5 (CCR5) inhibition ; CCR5 blockade ; Lymphocyte chemotaxis
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：22
- 期：10
- 页码：1829-1835
- 全文大小：747 K
文摘
- •
Maraviroc administration is feasible in pediatric allogeneic transplant recipients
- •
Maraviroc at a dose of ~300 mg/m2 achieves acceptable plasma levels and functional blockade of chemokine receptor type 5
- •
Maraviroc may be helpful in preventing acute visceral graft-versus-host disease in children with pre-existing enteropathy